There is no more eagerly awaited question in cardiovascular medicine than the clinical role of the PCSK9 inhibitors. The first reports from a series of outcomes trials are not due until next year. But two large genetic studies published this week deliver strong indirect evidence that PCSK9 inhibitors will likely have a clinical profile similar ...
Genetic studies offer hint of clinical benefits-and risks- of PCSK9 inhibitors
By Larry Husten
1 Dec 2016